The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria

ESMO Open. 2024 Sep;9(9):103725. doi: 10.1016/j.esmoop.2024.103725. Epub 2024 Sep 5.

Authors

A B Apolo¹, J Bellmunt², L Cordes¹, S Gupta³, T Powles⁴, J E Rosenberg⁵, M S Van Der Heijden⁶

Affiliations

¹ Center for Cancer Research, National Cancer Institute, Bethesda.
² Dana Farber Cancer Institute, Boston.
³ Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
⁴ Barts Cancer Centre, London, UK. Electronic address: [email protected].
⁵ Memorial Sloan Kettering, New York, USA.
⁶ National Cancer Institute (NKI), Amsterdam, the Netherlands.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal* / pharmacology
Antibodies, Monoclonal* / therapeutic use
Antibodies, Monoclonal, Humanized* / pharmacology
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Transitional Cell / drug therapy
Carcinoma, Transitional Cell / pathology
Humans
Male
Urinary Bladder Neoplasms / drug therapy
Urinary Bladder Neoplasms / pathology
Urologic Neoplasms / drug therapy
Urologic Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab
Antibodies, Monoclonal
enfortumab vedotin
Antineoplastic Agents, Immunological

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States